SRRK
Scholar Rock Holding CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.52B
P/E Ratio
—
EPS
$-3.29
Beta
0.69
52W High
$51.62
52W Low
$27.07
50-Day MA
$46.14
200-Day MA
$40.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-208.44M |
| EBITDA | $-382.99M |
| Operating Margin | 0.00% |
| Return on Equity | -123.10% |
| Return on Assets | -54.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.26 |
| Price-to-Book | 22.71 |
| Price-to-Sales (TTM) | 13.14 |
| EV/Revenue | 8.22 |
| EV/EBITDA | -2.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $119.30M |
| Float | $95.54M |
| % Insiders | 0.87% |
| % Institutions | 106.44% |
Historical Volatility
HV 10-Day
27.48%
HV 20-Day
25.21%
HV 30-Day
65.62%
HV 60-Day
56.31%
HV Rank
44.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($57.73 target)
3
Strong Buy13
BuyData last updated: 4/30/2026